Why the study?
What are the characteristics and management strategies for dipyridamole-induced headache in patients undergoing secondary stroke prevention?
What are the characteristics and management strategies for dipyridamole-induced headache in patients undergoing secondary stroke prevention?
Dipyridamole frequently causes early headaches leading to treatment discontinuation, which can be mitigated by patient education and slow dose titration rather than acetaminophen.
Dipyridamole-related headaches may reduce adherence in secondary stroke prevention; leaves open optimal mitigation beyond titration and education.
The combination of aspirin and dipyridamole is more effective in secondary stroke prevention than aspirin monotherapy. Headache is a frequent early adverse event in patients treated with dipyridamole. In the European Stroke Prevention Study 2, 8% of patients terminated treatment with dipyridamole due to headache compared with 2.1% with placebo. Dipyridamole induces headache more frequently in persons suffering from migraine than those without a primary headache. One way to reduce headache burden is to titrate dipyridamole slowly. Acetaminophen, however, is not effective in treating dipyridamole-induced headache. The optimal strategy to avoid early treatment termination and increase compliance is patient information about the occurrence and limited duration of headache and dose titration.
No takes yet. Share an insight, caveat, or question.
Diener et al. (2007) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: